A Decade of Evolution in Non-Small Cell Lung Cancer Treatment Standards in China and the US (2016–2026)
Non-small cell lung cancer (NSCLC) accounts for the vast majority of lung cancer cases. Over the past decade, its treatment has gradually shifted from a chemotherapy-dominated approach toward precision medicine guided by molecular profiling, PD-L1 expression, and disease stage.
Around 2016, the main treatment options for advanced NSCLC included platinum-based chemotherapy, targeted therapies for EGFR and ALK alterations, and immune checkpoint inhibitors, which were just beginning to enter clinical practice.
By 2026, treatment strategies have been established for multiple molecular subtypes, including EGFR, ALK, ROS1, RET, MET, BRAF, KRAS, and HER2. Immunotherapy has also expanded from advanced disease to selected patients with early-stage and locally advanced NSCLC.
China and the United States have shared a substantial body of international clinical evidence throughout this period. However, differences remain in drug development, regulatory approval, guideline recommendations, and patient access.
In this article, DengYueMed reviews the evolution in non-small cell lung cancer treatment standards from 2016 to 2026, examining developments across different stages of the disease and comparing treatment progress in China and the US.
01. The Treatment Landscape: From Chemotherapy-Dominated Care to Molecular Profiling and Comprehensive Disease Management
Over the past decade, the evolution in non-small cell lung cancer treatment standards has involved a transition from chemotherapy-dominated care to targeted therapy and immunotherapy, followed by the expansion of these approaches into earlier stages of the disease.
This transformation has been driven not only by new drug approvals, but also by advances in molecular testing, breakthroughs in clinical research, and a shift in treatment goals—from controlling advanced disease to reducing the risk of recurrence in earlier-stage patients.
In 2015, nivolumab and pembrolizumab received FDA approval for selected patients with previously treated NSCLC, marking the beginning of immunotherapy’s entry into lung cancer clinical practice. Since then, immunotherapy has progressively expanded into first-line treatment and earlier stages of the disease.
Several key clinical trials and regulatory approvals have shaped the evolution in non-small cell lung cancer treatment standards over the past decade:
| Year | Key Development | Impact on Treatment Standards |
|---|---|---|
| 2016 | Pembrolizumab received FDA approval for first-line treatment of patients with advanced NSCLC and high PD-L1 expression | Immunotherapy expanded from later-line treatment into the first-line setting |
| 2017–2018 | KEYNOTE-189, KEYNOTE-407, and other trials demonstrated the benefits of immunotherapy combined with chemotherapy | Immunotherapy plus chemotherapy became an important first-line option for advanced NSCLC without actionable driver mutations |
| 2018 | The PACIFIC trial established the role of durvalumab after concurrent chemoradiotherapy in unresectable stage III NSCLC without disease progression | Consolidation immunotherapy after chemoradiotherapy became an important standard treatment pathway |
| 2020 | The ADAURA trial showed that adjuvant osimertinib improved disease-free survival in patients with resected EGFR-mutated NSCLC; the treatment subsequently received FDA approval | EGFR-targeted therapy expanded from advanced disease into the adjuvant setting |
| 2022 | The CheckMate 816 trial supported neoadjuvant nivolumab plus chemotherapy for resectable NSCLC | Immunotherapy began to enter the preoperative treatment setting |
| 2023–2024 | KEYNOTE-671 and AEGEAN advanced perioperative immunotherapy, while the LAURA trial established the value of osimertinib after chemoradiotherapy in EGFR-mutated stage III NSCLC | Immunotherapy and targeted therapy expanded further into early-stage and locally advanced disease |
| 2025–2026 | Treatments targeting KRAS G12C and HER2 continued to advance, while research into bispecific antibodies and antibody-drug conjugates (ADCs) progressed | Treatment strategies expanded toward less common molecular subtypes, resistant disease, and precision combination therapy |
At the same time, the scope of molecular testing expanded from an early focus on EGFR and ALK to include ROS1, BRAF, MET exon 14 skipping, RET, NTRK, KRAS G12C, and HER2, among other targets.
Technologies such as tissue-based testing, next-generation sequencing (NGS), and liquid biopsy have provided additional tools for patient selection, treatment decisions, and the analysis of resistance mechanisms.
| Dimension | Around 2016 | By 2026 |
|---|---|---|
| Treatment decision-making | Primarily based on disease stage, histology, and a limited number of driver mutations | Integrates disease stage, molecular subtype, PD-L1 expression, and treatment history |
| Driver-positive disease | Targeted therapies for EGFR and ALK were becoming established | Precision treatments targeting multiple molecular subtypes, alongside resistance management |
| Driver-negative disease | Chemotherapy remained the foundation, with immunotherapy gradually entering clinical practice | Immunotherapy monotherapy and immunotherapy combined with chemotherapy |
| Unresectable stage III disease | Definitive chemoradiotherapy was the core treatment | Consolidation treatment after chemoradiotherapy, with subsequent management guided by molecular subtype |
| Early-stage resectable disease | Surgery, with adjuvant chemotherapy for selected patients | Multimodal treatment involving neoadjuvant, adjuvant, and perioperative approaches |
| Testing methods | Primarily focused on EGFR and ALK | Multigene testing, PD-L1 testing, and liquid biopsy |
China has also gradually developed its own innovative drug research and development system during this transformation.
From initially introducing and adopting overseas targeted therapies and immunotherapies to bringing domestically developed EGFR-TKIs such as aumolertinib and furmonertinib, as well as domestic PD-1 antibodies, KRAS G12C inhibitors, and bispecific antibodies, into clinical practice.
China’s innovative drug development is moving beyond following international treatment advances toward greater participation in global clinical research and innovation.
02. Advanced Driver-Positive NSCLC: From Single-Target Inhibition to First-Line Combination Therapy and Resistance Management
Driver-positive NSCLC has been one of the areas with the most concentrated progress in precision medicine over the past decade. EGFR- and ALK-positive disease are particularly representative examples, highlighting the evolution in non-small cell lung cancer treatment standards through increasingly precise targeted therapies and more individualized treatment strategies.
2.1 EGFR-Mutated NSCLC: From First-Generation TKIs to Third-Generation Targeted and Combination Therapies
Around 2016, gefitinib, erlotinib, and afatinib were important treatment options for advanced NSCLC with sensitizing EGFR mutations. However, acquired resistance frequently developed following treatment with first- or second-generation EGFR-TKIs. The T790M mutation was one of the common resistance mechanisms.
The third-generation EGFR-TKI osimertinib represented a major breakthrough in this area. It was initially approved in the United States in 2015 for advanced NSCLC with EGFR T790M-positive disease. In China, it received approval for the corresponding indication in 2017.
The FLAURA trial, reported in 2017, further changed the first-line treatment landscape. Osimertinib significantly improved progression-free survival (PFS) compared with gefitinib or erlotinib, and subsequent follow-up demonstrated an overall survival benefit. These findings helped establish osimertinib as an important first-line treatment option.
China also gradually developed its own portfolio of domestically developed third-generation EGFR-TKIs.
Drugs such as aumolertinib and furmonertinib entered clinical practice. Furmonertinib received approval in 2022 for first-line treatment of locally advanced or metastatic NSCLC with sensitizing EGFR mutations, demonstrating the expansion of China’s domestically developed innovative therapies into the first-line setting.
| Drug or Treatment Regimen | Representative Trial | Treatment Significance |
|---|---|---|
| Gefitinib, erlotinib | Multiple EGFR-mutated NSCLC studies | Established the EGFR-TKI treatment pathway |
| Osimertinib | FLAURA | Advanced third-generation EGFR-TKIs into first-line treatment |
| Osimertinib | ADAURA | Extended targeted therapy into the postoperative adjuvant setting |
| Aumolertinib, furmonertinib | Chinese registration trials | Expanded the clinical use of domestically developed third-generation EGFR-TKIs |
| Osimertinib plus chemotherapy | FLAURA2 | Explored treatment intensification in the first-line setting |
| Amivantamab plus lazertinib | MARIPOSA | Introduced another first-line combination strategy for EGFR-mutated NSCLC |
Progress in first-line treatment has not eliminated the challenge of acquired resistance.
When disease progression occurs, further assessment is needed to determine whether EGFR-related alterations, bypass pathway activation, or histologic transformation are present. Tissue re-biopsy and circulating tumor DNA (ctDNA) testing therefore play important roles in subsequent treatment decisions.
In 2024, the US FDA approved osimertinib in combination with platinum-based chemotherapy for first-line treatment of advanced NSCLC with EGFR exon 19 deletions or L858R mutations. The FLAURA2 trial showed a median PFS of 25.5 months in the combination group, compared with 16.7 months with osimertinib monotherapy.
The MARIPOSA trial evaluated amivantamab in combination with lazertinib as first-line treatment for advanced NSCLC with sensitizing EGFR mutations.
By 2026, discussions surrounding first-line EGFR-mutated NSCLC treatment had moved beyond comparisons between generations of monotherapy to focus increasingly on the benefits, safety profiles, and appropriate patient populations for combination regimens.
2.2 ALK-Positive NSCLC: From Crizotinib to Next-Generation Inhibitors
Around 2016, crizotinib was an important treatment option for advanced ALK-positive NSCLC. However, its ability to control disease in the central nervous system was limited, making brain metastases a major clinical challenge.
In 2017, the ALEX trial showed that alectinib significantly improved PFS compared with crizotinib and reduced the risk of central nervous system progression. This helped establish alectinib as an important first-line treatment option.
Subsequently, brigatinib, ensartinib, and lorlatinib further expanded the treatment landscape.
The five-year follow-up of the CROWN trial showed that median PFS had not yet been reached in the lorlatinib group, compared with 9.1 months in the crizotinib group. The five-year PFS rates were 60% and 8%, respectively.
These findings highlight the important advantages of next-generation ALK inhibitors in long-term disease control and the management of brain metastases.
2.3 Other Driver Mutations: The Gradual Establishment of Multi-Target Precision Treatment
Beyond EGFR and ALK, treatment options have gradually emerged for multiple other molecular subtypes.
| Molecular Target | Representative Drugs | Treatment Progress |
|---|---|---|
| ROS1 fusion | Crizotinib, entrectinib, repotrectinib | Established targeted treatment options, with improved central nervous system control |
| RET fusion | Selpercatinib, pralsetinib | Expanded treatment from chemotherapy to selective RET inhibitors |
| MET exon 14 skipping | Savolitinib, capmatinib, tepotinib | Provided targeted options for MET alterations |
| BRAF V600E | Dabrafenib plus trametinib | Established a combination targeted treatment approach |
| KRAS G12C | Sotorasib, adagrasib, glecirasib, fulzerasib | Introduced targeted treatment options for KRAS G12C-mutated disease |
| HER2 mutation | Trastuzumab deruxtecan, sevabertinib, and others | Advanced the development of ADCs and mutation-selective targeted therapies |
| EGFR exon 20 insertion | Sunvozertinib, amivantamab, and others | Established treatment pathways distinct from those used for common sensitizing EGFR mutations |
China has achieved notable progress in the development of domestically developed KRAS G12C inhibitors.
Fulzerasib and glecirasib received conditional approval from China’s National Medical Products Administration (NMPA) in 2025 for patients with advanced KRAS G12C-mutated NSCLC who had previously received systemic treatment.
HER2-mutated NSCLC is another area of note in the regulatory progress of China and the United States in 2026.
Sevabertinib received FDA approval in September 2026 for selected patients with locally advanced or metastatic non-squamous NSCLC harboring HER2-activating mutations. It was subsequently approved in China in November of the same year.
With advances in molecular testing, treatment is increasingly moving toward a precision approach based on multiple targets, more specific molecular subtypes, and resistance mechanisms.
03. Advanced Driver-Negative NSCLC: Immunotherapy Reshapes First-Line Treatment Standards
For patients with advanced NSCLC who do not have an actionable driver mutation, immune checkpoint inhibitors have been among the most important treatment breakthroughs of the past decade.
3.1 High PD-L1 Expression: Immunotherapy Monotherapy Enters the First-Line Setting
In 2016, the KEYNOTE-024 trial demonstrated that pembrolizumab monotherapy was superior to platinum-based chemotherapy in patients with advanced NSCLC, PD-L1 tumor proportion score (TPS) of at least 50%, and no EGFR or ALK driver alterations. At five-year follow-up, the five-year overall survival rates were 31.9% and 16.3%, respectively.
These findings established a first-line immunotherapy monotherapy pathway for selected patients with high PD-L1 expression.
3.2 Immunotherapy Plus Chemotherapy: Expanding the Eligible Patient Population
For patients with low or negative PD-L1 expression, the benefits of immunotherapy monotherapy may be limited. Immunotherapy combined with chemotherapy therefore became an important first-line treatment option.
| Trial | Patient Population | Main Regimen and Significance |
|---|---|---|
| KEYNOTE-024 | Advanced NSCLC with PD-L1 TPS ≥50% | Pembrolizumab monotherapy established a first-line immunotherapy pathway |
| KEYNOTE-189 | Metastatic non-squamous NSCLC | Pembrolizumab plus pemetrexed and platinum-based chemotherapy |
| KEYNOTE-407 | Metastatic squamous NSCLC | Pembrolizumab plus carboplatin and a taxane |
| CheckMate-227 | Metastatic NSCLC | Evaluated dual immunotherapy, including nivolumab plus ipilimumab |
| IMpower150 | Metastatic non-squamous NSCLC | Explored the combination of immunotherapy, anti-angiogenic therapy, and chemotherapy |
KEYNOTE-189 and KEYNOTE-407 provided important evidence for non-squamous and squamous NSCLC, respectively, supporting immunotherapy plus chemotherapy as a first-line strategy for a broader patient population.
These two trials helped establish immunotherapy plus chemotherapy as an important first-line treatment approach for advanced driver-negative NSCLC. The pembrolizumab-based combination regimens received FDA approval in 2018 and subsequently entered clinical practice in China.
Other studies further expanded the treatment landscape.
The CheckMate-227 trial explored dual immunotherapy with nivolumab and ipilimumab. The IMpower150 trial demonstrated that atezolizumab combined with bevacizumab and chemotherapy could provide benefits for selected patients with advanced non-squamous NSCLC.
3.3 China’s Immunotherapy Development: From Adoption to Domestic Innovation
China has made rapid progress in the development of PD-1 inhibitors, contributing to the evolution in non-small cell lung cancer treatment standards by expanding immunotherapy options and increasing the role of China-developed therapies in clinical practice.
Domestically developed drugs such as sintilimab, tislelizumab, camrelizumab, and toripalimab have received approval and have been evaluated in different clinical studies exploring their use in advanced NSCLC.
For example, sintilimab combined with pemetrexed and platinum-based chemotherapy has been used as first-line treatment for non-squamous NSCLC. Related studies have provided clinical evidence in Chinese patient populations. Tislelizumab and other agents have also accumulated global clinical data through international multicenter studies.
An important development is China’s continued exploration of new combination mechanisms based on immunotherapy.
Ivonescimab is a bispecific antibody targeting PD-1 and VEGF, combining immune modulation with anti-angiogenic activity. Its clinical development in EGFR-mutated NSCLC following EGFR-TKI resistance highlights the growing role of bispecific antibodies and international interest in China’s innovative drug development.
04. Unresectable Stage III NSCLC: From Definitive Chemoradiotherapy to Consolidation Treatment
Patients with unresectable stage III NSCLC are generally unable to undergo complete surgical resection. The treatment goal is to achieve long-term disease control.
Around 2016, definitive concurrent chemoradiotherapy was an important standard treatment approach. However, there was not yet a universally established consolidation immunotherapy pathway following chemoradiotherapy.
4.1 PACIFIC: Establishing Consolidation Immunotherapy After Chemoradiotherapy
The PACIFIC trial, reported in 2017, changed the treatment approach for unresectable stage III NSCLC. It enrolled patients whose disease had not progressed following definitive concurrent chemoradiotherapy and compared consolidation treatment with durvalumab against placebo.
The study showed that durvalumab significantly improved both PFS and overall survival (OS). Subsequently, durvalumab after chemoradiotherapy became an important standard treatment option for eligible patients with unresectable stage III NSCLC.
Its significance lies in the expansion of immunotherapy from metastatic disease into a locally advanced setting where treatment is delivered with curative intent.
4.2 LAURA: A New Treatment Pathway for Patients with EGFR-Mutated Disease
Although PACIFIC established consolidation immunotherapy as an important treatment approach, patients with EGFR-mutated disease require different treatment considerations.
The LAURA trial, reported in 2024, focused on patients with unresectable stage III NSCLC harboring EGFR exon 19 deletions or L858R mutations whose disease had not progressed following platinum-based chemoradiotherapy. Median PFS was 39.1 months in the osimertinib group, compared with 5.6 months in the placebo group.
The US FDA subsequently approved osimertinib for this treatment setting.
This reflects the evolution in non-small cell lung cancer treatment standards: post-chemoradiotherapy management of unresectable stage III NSCLC is no longer uniform but increasingly guided by the patient’s driver mutation status and response to prior treatment.
05. Early-Stage Resectable NSCLC: From Surgery to Perioperative Management
Around 2016, surgery was the main treatment approach for early-stage NSCLC. Some patients at high risk of postoperative recurrence received platinum-based adjuvant chemotherapy.
Over the past decade, targeted therapy and immunotherapy have gradually entered both the preoperative and postoperative settings.
5.1 EGFR-Targeted Therapy Enters the Postoperative Adjuvant Setting
The ADAURA trial represented a major breakthrough in the treatment of early-stage EGFR-mutated NSCLC.
The study enrolled patients with completely resected stage IB–IIIA NSCLC harboring EGFR exon 19 deletions or L858R mutations. The results showed that adjuvant osimertinib significantly reduced the risk of disease recurrence.
Subsequent follow-up showed five-year OS rates of 88% in the osimertinib group and 78% in the placebo group. The FDA approved osimertinib for adjuvant treatment of EGFR-mutated NSCLC following complete resection in 2020, and China approved the corresponding indication in 2021.
This marked the expansion of EGFR-targeted therapy beyond advanced disease into the postoperative setting, with the aim of reducing the risk of recurrence in patients with earlier-stage disease.
5.2 Neoadjuvant Immunotherapy Changes Preoperative Treatment Strategies
One of the key sources of evidence for immunotherapy in early-stage NSCLC came from the CheckMate 816 trial.
The study showed that, in patients with resectable NSCLC, neoadjuvant nivolumab plus platinum-based chemotherapy significantly improved the pathological complete response (pCR) rate compared with chemotherapy alone: 24.0% versus 2.2%. The combination also improved event-free survival (EFS).
In 2022, the FDA approved nivolumab plus platinum-based chemotherapy as neoadjuvant treatment for selected patients with resectable NSCLC. This marked an important step in the expansion of immunotherapy from advanced disease into the preoperative setting.
Subsequently, KEYNOTE-671, AEGEAN, and CheckMate 77T further explored perioperative immunotherapy, involving immunotherapy combined with chemotherapy before surgery, followed by continued immunotherapy after surgery.
The KEYNOTE-671 trial showed that perioperative pembrolizumab combined with chemotherapy improved EFS and OS in patients with resectable stage II–III NSCLC.
In 2023, the FDA approved this perioperative treatment regimen. The AEGEAN trial also provided evidence supporting a perioperative strategy involving durvalumab combined with chemotherapy.
5.3 Chinese Clinical Research Advances Perioperative Immunotherapy
China has also actively participated in clinical research on immunotherapy for early-stage NSCLC.
The NEOTORCH trial evaluated perioperative toripalimab combined with chemotherapy in patients with resectable NSCLC, providing important clinical evidence for Chinese patient populations.
In addition, the IMpower010 trial supported the use of atezolizumab as adjuvant treatment for selected patients following surgery, while the KEYNOTE-091 trial evaluated the value of adjuvant pembrolizumab.
The US FDA approved the corresponding adjuvant treatment indications in 2021 and 2023, respectively.
06. Comparing Treatment Standards in China and the US: Converging Clinical Evidence, but Differences in Approval and Access
The evolution in non-small cell lung cancer treatment standards in China and the United States has generally been based on the same body of international clinical evidence.
However, the two countries differ in their guideline systems, drug approval processes, participation in clinical research, and actual patient access to treatment.
6.1 Guidelines and Clinical Practice
Clinical practice in the United States primarily refers to guidelines from organizations such as the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO). New clinical trial results and FDA-approved indications are often incorporated into guideline discussions relatively quickly.
In China, clinical practice primarily refers to guidelines from the Chinese Society of Clinical Oncology (CSCO), the Chinese Medical Association, and other professional organizations. Recommendations are developed in consideration of NMPA approvals, domestic clinical evidence, and the availability of medicines.
6.2 Drug Approval and Domestic Innovation
The United States has a first-mover advantage in global pivotal clinical research and innovative drug regulatory approvals, with some important medicines receiving approval there first.
China, meanwhile, has accelerated the approval of innovative medicines through mechanisms such as priority review and conditional approval.
Chinese pharmaceutical companies have gradually established R&D capabilities in areas including EGFR-TKIs, PD-1 antibodies, KRAS G12C inhibitors, and bispecific antibodies. Domestic companies are also moving beyond drug introduction and participation in clinical trials toward global multicenter studies, overseas regulatory submissions, and licensing-out partnerships.
6.3 Drug Accessibility: Approval, Guideline Recommendations, and Actual Use Are Not the Same
Regulatory approval is only one part of treatment accessibility. Whether patients can actually receive a treatment also depends on factors such as public insurance coverage, commercial insurance, hospital formulary access, testing capabilities, medicine supply, and regional healthcare resources.
| Dimension | United States | China |
|---|---|---|
| Major guidelines | NCCN, ASCO, and others | CSCO, Chinese Medical Association, and others |
| Drug regulator | FDA | NMPA |
| Clinical research | A major originator and participant in global pivotal registration studies | Increasing participation in international multicenter studies and active domestic research |
| Innovative drug development | Established R&D systems across multinational pharmaceutical companies and biotechnology firms | Growing domestic innovative drug development and international licensing partnerships |
| Drug accessibility | Influenced by commercial insurance, Medicare, and other factors | Influenced by the National Reimbursement Drug List (NRDL), hospital access, and regional resources |
| Clinical practice | New evidence is often incorporated into guideline discussions relatively quickly | Implementation takes into account domestic approved indications and actual availability |
Overall, the differences between China and the US are gradually shifting from whether a particular medicine is available to whether patients can obtain timely access to appropriate testing, treatment, and long-term disease management.
07. Future Trends: Resistance Management, ADCs, and Precision Perioperative Treatment
By 2026, the evolution in non-small cell lung cancer treatment standards is moving toward multiple targets, multiple mechanisms, and comprehensive disease management. Several areas are likely to shape future developments.
1. Resistance Mechanism-Guided Subsequent Treatment
Targeted therapies for EGFR, ALK, and other molecular alterations continue to face the challenge of acquired resistance. Tissue re-biopsy, ctDNA testing, and NGS may help identify resistance mutations, bypass pathway activation, and histologic transformation, providing a basis for subsequent treatment decisions.
2. ADCs Expand Treatment Options
Antibody-drug conjugates (ADCs) deliver cytotoxic payloads through targeted antibodies and have become an important area of lung cancer drug development. Trastuzumab deruxtecan is already used in HER2-mutated NSCLC, while ADCs targeting TROP2 and other targets continue to be evaluated in clinical studies.
3. Bispecific Antibodies and Combination Therapy
PD-1/VEGF bispecific antibodies aim to integrate immune modulation with anti-angiogenic mechanisms. Chinese-developed agents such as ivonescimab have helped advance this field. Further clinical evidence is still needed to establish their long-term efficacy and the patient populations most likely to benefit.
4. Greater Precision in Perioperative Treatment
Treatment of early-stage NSCLC will increasingly take into account driver mutations, PD-L1 expression, tumor stage, and recurrence risk. The perioperative use of EGFR-targeted therapy and immunotherapy combined with chemotherapy continues to be explored.
Meanwhile, minimal residual disease (MRD) and ctDNA testing may help assess postoperative recurrence risk. However, prospective studies are still needed to validate their value in guiding treatment decisions.
5. The Global Expansion of China’s Innovative Medicines
China’s NSCLC drug development is expanding from established molecular targets into areas such as novel targets, bispecific antibodies, and ADCs. With the growth of international multicenter clinical trials, drug licensing, and global registration partnerships, China’s innovative medicines are expected to play an increasingly important role in global NSCLC drug development.
Conclusion
From 2016 to 2026, NSCLC treatment gradually moved beyond chemotherapy-dominated care toward targeted therapy, immunotherapy, and comprehensive perioperative treatment. EGFR- and ALK-targeted medicines, together with immunotherapies, have continued to reshape clinical practice.
Key trials such as PACIFIC, ADAURA, and LAURA have also helped extend treatment goals from controlling advanced disease to reducing the risk of recurrence in earlier-stage patients.
Over the past decade, the United States has continued to drive global innovative drug development, while China’s innovative pharmaceutical sector has accelerated its participation in international clinical research and drug partnerships.
As progress continues in ADCs, bispecific antibodies, resistance management, and precision treatment, the global NSCLC treatment landscape will continue to evolve.
As a global pharmaceutical distributor, DengYueMed will continue to follow developments in drug research, regulatory approvals, and clinical applications in China and around the world, with a focus on how innovative medicines can cross regional boundaries and contribute to new pharmaceutical access and collaboration opportunities.

Explore Global Advances in Lung Cancer Treatment
FAQ about Evolution in Non-Small Cell Lung Cancer Treatment Standards
1. What factors influence treatment decisions for NSCLC patients?
Treatment decisions depend on disease stage, histological subtype, molecular alterations, PD-L1 expression, and the patient’s overall health. These factors help determine whether targeted therapy, immunotherapy, chemotherapy, or surgery is appropriate.
2. Which biomarkers are commonly tested in NSCLC?
Common biomarkers include EGFR, ALK, ROS1, RET, MET, BRAF, KRAS, and HER2 alterations, as well as PD-L1 expression. Testing helps identify patients who may benefit from targeted therapies or immunotherapy.
3. How is treatment adjusted when NSCLC develops drug resistance?
Doctors may recommend tissue re-biopsy or liquid biopsy to identify resistance mechanisms, such as secondary mutations or bypass pathway activation. The results can help guide subsequent treatment strategies.
4. What should international patients know about accessing NSCLC medicines in China?
Access depends on NMPA approval, hospital availability, prescription requirements, and individual clinical assessment. International patients should also consider import regulations and medicine access requirements in their home countries.
5. How are China-developed drugs influencing global NSCLC treatment?
China-developed EGFR-TKIs, PD-1 inhibitors, KRAS G12C inhibitors, and bispecific antibodies are contributing to clinical research and treatment innovation. International multicenter trials, licensing partnerships, and overseas regulatory submissions are helping bring these developments to broader global attention.
References
I. Clinical Guidelines and Treatment Standards
- Oncology Society of Chinese Medical Association. Guideline for Clinical Diagnosis and Treatment of Lung Cancer (2026 Edition). Chinese Journal of Oncology. 2026;48(9):1023–1059. DOI: https://doi.org/10.3760/cma.j.cn112152-20260511-00228.
- Riely GJ, et al. Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2026;24(4):e260017. DOI: https://doi.org/10.6004/jnccn.2026.0017.
II. EGFR- and ALK-Targeted Therapy
- Soria JC, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (FLAURA). New England Journal of Medicine. 2018;378:113–125.
- Peters S, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer (ALEX). New England Journal of Medicine. 2017;377:829–838.
- Planchard D, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC (FLAURA2). New England Journal of Medicine. 2023;389:1935–1948.
- Lu S, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC (LAURA). New England Journal of Medicine. 2024;391:585–597.
- Wu YL, et al. Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer (ADAURA). New England Journal of Medicine. 2020;383:1711–1723.
III. Immunotherapy and Advanced NSCLC
- Reck M, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer (KEYNOTE-024). New England Journal of Medicine. 2016;375:1823–1833.
- Gandhi L, et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer (KEYNOTE-189). New England Journal of Medicine. 2018;378:2078–2092.
- Paz-Ares L, et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer (KEYNOTE-407). New England Journal of Medicine. 2018;379:2040–2051.
IV. Locally Advanced and Early-Stage NSCLC Treatment
- Antonia SJ, et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer (PACIFIC). New England Journal of Medicine. 2017;377:1919–1929.
- Forde PM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer (CheckMate 816). New England Journal of Medicine. 2022;386:1973–1985.
- Wakelee H, et al. Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer (KEYNOTE-671). New England Journal of Medicine. 2023.
- Heymach JV, et al. Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer (AEGEAN). New England Journal of Medicine. 2023.
V. Regulatory Approvals and China’s Innovative Drug Development
- U.S. Food and Drug Administration (FDA). FDA Oncology Center of Excellence: Oncology (Cancer)/Hematologic Malignancies Approval Notifications.
- U.S. Food and Drug Administration (FDA). FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer. September 9, 2026.
- Bayer. Sevabertinib Approved in China as First-Line Treatment for Patients with HER2-Mutant Non-Small Cell Lung Cancer. November 4, 2026.
